Elutia Inc. has entered into a definitive agreement to sell its BioEnvelope business, including EluPro™ and CanGaroo® bioenvelopes, to Boston Scientific Corporation for $88 million in cash. The transaction, announced on September 9, 2025, is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
The bioenvelopes are designed to protect patients receiving implantable medical devices, representing a key application of Elutia's proprietary drug-eluting biologic technology platform. According to Dr. Randy Mills, CEO of Elutia, the successful commercialization of EluPro has demonstrated the platform's scalability and market acceptance.
Commercial Success Validates Technology Platform
EluPro has achieved significant commercial traction since its launch, securing seven national group purchasing organization contracts and obtaining more than 160 value analysis committee approvals. "With the successful launch of EluPro, seven national group purchasing organization contracts secured and more than 160 value analysis committee approvals, we have shown that we can develop, manufacture and commercialize these highly regulated breakthrough products, and that they are valued by physicians," said Dr. Mills.
The transaction underscores the value of Elutia's proprietary drug-eluting biologic technology platform and provides validation for the company's approach to developing medical device compatibility solutions.
Strategic Focus on Breast Reconstruction Market
The acquisition proceeds will enable Elutia to advance its NXT-41 and NXT-41x pipeline without shareholder dilution. These novel technologies are designed to address the $1.5 billion U.S. breast reconstruction market, helping women recovering from breast cancer.
"Now, with a transformed balance sheet, an established commercial engine and a proven team, we are ready to repeat our success with NXT-41x. This novel technology is designed to transform the $1.5 billion breast reconstruction market and help women recovering from breast cancer to thrive without compromise," added Dr. Mills.
Financial Transformation and Strategic Benefits
The transaction provides several strategic advantages for Elutia:
Balance Sheet Transformation: The deal positions Elutia to eliminate outstanding debt and substantially resolve litigation from the company's previously divested Orthobiologics business, while significantly reducing the company's burn rate.
Non-Dilutive Funding: The $88 million proceeds fully fund the advancement and commercialization of NXT-41 and NXT-41x, creating a clear path to cash-flow positive operations without requiring additional shareholder dilution.
Strategic Focus: The transaction enables Elutia to dedicate resources toward advancing its SimpliDerm franchise and first-in-class drug-eluting pipeline in the breast reconstruction market, leveraging the company's considerable experience developing EluPro.
About the Companies
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and patients. The company's mission focuses on humanizing medicine so patients can thrive without compromise.
BofA Securities is acting as financial advisor to Elutia in the sale of its BioEnvelope business. The company's management team will provide updates at the H.C. Wainwright 27th Annual Global Investment Conference on September 10 at 9:30 a.m. Eastern Time.
